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Background: Inosine and guanosine monophosphate nucleotides are convenient sources of the umami flavor,
with attributed beneficial health effects that have renewed commercial interest in nucleotide fermentations.
Accordingly, several bacterial strains that excrete high levels of inosine and guanosine nucleosides are currently
used in the food industry for this purpose.
Results: In the present study, we show that the filamentous fungus Ashbya gossypii, a natural riboflavin
overproducer, excretes high amounts of inosine and guanosine nucleosides to the culture medium. Following a
rational metabolic engineering approach of the de novo purine nucleotide biosynthetic pathway, we increased the
excreted levels of inosine up to 27-fold.
Conclusions: We generated Ashbya gossypii strains with improved production titers of inosine and guanosine. Our
results point to Ashbya gossypii as the first eukaryotic microorganism representing a promising candidate,
susceptible to further manipulation, for industrial nucleoside fermentation.
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Purine nucleotides are of significant economic interest
for the applied biotechnology industry because they are
used as foodstuff additives with flavouring, nutritional
and pharmaceutical properties [1]. Inosine monopho-
sphate (IMP) and guanosine monophosphate (GMP)
have flavour enhancer capabilities that, in combination
with monosodium glutamate, increase the umami fla-
vour synergistically [2]. Moreover, both inosine and
guanosine have beneficial health effects, related to their
antioxidant, neuroprotective, cardiotonic and immuno-
modulatory properties [3-5]. It was estimated that ap-
proximately 22,000 tons of GMP and IMP were produced
in 2010 [1].
Currently, purine nucleotides are obtained at industrial
level mainly by microbial fermentation, either by RNA
extraction and further breakdown into free nucleotides
or by improved metabolic biosynthesis, subsequent* Correspondence: revuelta@usal.es
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article, unless otherwise stated.excretion of the nucleosides to the culture medium, and
further chemical or enzymatic phosphorylation [1]. In
recent years, the significant enhancement of nucleoside
production through metabolic engineering approaches
in different microorganisms proved that this production
process is the most efficient [6,7].
Most microorganisms synthesize purine nucleotides in
two distinct pathways. First, purines are synthesized de
novo, beginning with simple starting materials such as
amino acids and bicarbonate. Alternatively, purine bases,
either released by the hydrolytic degradation of nucleic
acids and nucleotides or taken from the culture medium,
can be recycled following the salvage pathway [8].
In the de novo purine pathway, a molecule of ribose-
5-phosphate is first converted through ten sequential
catalytic reactions into IMP, the first compound in the
pathway to have a completely formed purine ring sys-
tem. IMP can then be converted into either AMP or
GMP through the action of specific enzymes (Figure 1).
Additionally, through the action of nucleotidases, nucleo-
tides can be degraded into nucleosides that are either
secreted to the culture medium or further degraded tod Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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Figure 1 Simplified schematic representation of the de novo purine pathway in A. gossypii. Abbreviations used: ADE4 phosphoribosylpyrophosphate
(PRPP) amidotransferase, ADE12 adenylosuccinate synthase, IMD3 IMP dehydrogenase, GUA1 GMP synthase and PNP1 purine nucleoside
phosphorylase. The geometric shapes indicate the reactions for which the simulations using the genome-scale metabolic model iRL766 predicted an
increase in the metabolic flux upon optimization of the production of biomass, guanosine and inosine (triangles, squares and pentagons, respectively).
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for a review, see [8,9]).
Several bacterial strains that overproduce nucleotides
at industrial level have been developed by random muta-
genesis and/or rational genetic modifications in Bacillus
subtilis [10], Bacillus amyloliquefaciens [11], Corynebac-
terium glutamicum [12], Corynebacterium ammonia-
genes [13] and Escherichia coli [7]. To date, metabolic
engineering approaches to these bacteria have targeted:
i) central metabolism ii) the de novo purine biosynthetic
pathway 3) the salvage purine pathway 4) regulator
genes and 5) nucleotide and nucleoside transporters [1].
Ashbya gossypii is a filamentous fungus considered to
be a paradigm of the environmentally friendly “White
Biotechnology” and is probably the most representative
example illustrating the importance of microbial meta-
bolic engineering to substitute chemical synthesis by a
much more convenient microbial production. Contrary
to what used to be the case several decades ago, at
present most of the world’s riboflavin production relies
on A. gossypii fermentation [14,15]. Additionally, it has
one of the smallest genomes of free-living eukaryotes
and a high level of similarity and gene order conserva-
tion (synteny) to the genome of the widely studied yeast
Saccharomyces cerevisiae [16]. The existence of efficient
gene targeting methods that allows the generation of
stable engineered strains and a broad variety of molecu-
lar tools mean that A. gossypii is an ideal unicellular –
eukaryotic- organism that is well suited for genetic ma-
nipulation and metabolic engineering [17-19]. In terms
of industrial suitability, it has been found that A. gossypiican be readily scaled up for large-scale metabolite pro-
duction [15]. Downstream processes are cheaper than in
most yeast and bacteria because A. gossypii undergoes
autolysis at low temperature and the mycelia can be re-
moved by simple filtration [20]. Moreover, A. gossypii is
able to use non-expensive waste products from other in-
dustrial processes as the sole carbon source [21]. Inter-
estingly, the fact that A. gossypii is a natural riboflavin
overproducer denotes a strong metabolic flux through
the purine pathway (given that GTP is the riboflavin-
limiting precursor) that could be redirected to accumu-
late nucleotides and nucleosides.
With all these advantages in mind, here we used a
metabolic engineering approach to the purine pathway
of A. gossypii aiming at generating strains with increased
production levels of nucleosides of potential interest for
the food biotechnological industry. In the present work,
we demonstrate that the wild-type A. gossypii excretes
high levels of the nucleosides guanosine and inosine to
the culture medium, while their respective intracellular
concentrations remain much lower. Furthermore, after
manipulation of the genes that code for the enzymes in
the de novo purine pathway, we generated strains with a
27-fold higher titer of excreted inosine than the wild-
type, showing that A. gossypii is a promising eukaryotic
candidate for industrial nucleoside production.
Results and discussion
Inosine and guanosine nucleosides are excreted to the
growth medium of A. gossypii. We have recently gener-
ated a genome-scale metabolic model of A. gossypii [22]
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initial growth phase to the late riboflavin-productive
phase. Interestingly, in that work we observed nucleoside
permeases to be significantly up-regulated during the
latter stage [22]. Here, we aimed at further corroborating
this prediction by analyzing the nucleosides excreted to
the extracellular medium during flask fermentations of
A. gossypii. As shown in Figure 2A, all the wild-type
strains tested excreted mg/L amounts of nucleosides to
the culture medium and these were almost exclusively
guanosine and inosine. Based, on these results, we de-
cided to use A4 (ATCC10895) as the parental strain for
further modifications because: i) it is the strain that ex-
cretes the highest levels of nucleosides to the medium
and ii) it is the best characterized wild type strain of A.
gossypii.B
A
Figure 2 Quantification of inosine and guanosine in wild-type strains.
A. Analysis of extracellular inosine and guanosine in different wild-type
strains of A. gossypii. grown for five days in flasks containing MA2 rich
medium. B. Time-course quantification of the excretion of inosine and
guanosine to the culture media of strain A4 grown in MA2. Error bars
represent the standard deviations of three independent experiments.A time-course analysis of A4 revealed a maximum in
nucleoside excretion on the 5th day, rapidly falling off
on around the 7th day of culture (Figure 2B); a similar
type of behavior was also observed for the other strains
tested (data not shown). These data suggest that the nu-
cleosides excreted during the initial growth stages might
be reincorporated to the cell, and then recycled to nucle-
otides through the salvage pathway, to support the
strongly active riboflavin synthesis that occurs during
the late stages of growth [22]. Alternatively, nucleoside
degradation could occur in the culture medium, where
cell lysis starts to take place at that stage [23]. However,
these hypotheses should be corroborated in further
experiments.
Metabolic engineering of the purine pathway improves
nucleoside excretion to the growth media of A. gossypii.
In order to determine the enzymes involved in nucleo-
side production, we used our computational genome-
scale metabolic model [22] to simulate situations with
three different objective functions; that is, to optimize
the production of biomass synthesis, inosine or guano-
sine. A total of 303 reactions are involved in biomass
production while only 76 and 78 respectively are pre-
dicted to maximize the production of inosine and
guanosine (Additional file 1: Table S1). As expected,
comparison of the three simulations revealed significant
differences in the metabolic fluxes along the different re-
actions of the purine biosynthetic pathway, shown sche-
matically in Figure 1. The flux through the genes
upstream of IMP in the de novo pathway (ADE4,
ADE16, etc.) was maximal in the three simulations, in
contrast to PNP1, which was minimum. Moreover, the
metabolic flux through ADE12 decreased when the pro-
duction of both inosine and guanosine was maximized.
Additionally, the flux through ISN1 was maximized in
simulations of inosine and guanosine production. On
the other hand, our simulations predicted that the flux
through IMD3 should be maximized to optimize guano-
sine and minimized for inosine production (Figure 1).
Based on these computer simulations, and considering
a predicted maximum flux as a target reaction/gene for
overexpression and a minimum flux as a target reaction/
gene for deletion, we next employed a rational metabolic
engineering approach to generate A. gossypii strains with
improved production titers. The genotypes of all the
strains generated in this work and their respective nu-
cleoside excretion levels are listed in Table 1.
As a first approach, we tested the nucleoside excretion
levels of an engineered strain (I0) in which the metabolic
flux through the purine pathway had been increased by
overpassing the adenine-mediated transcriptional repres-
sion of the ADE4 gene by eliminating the ATP/GTP
feedback inhibition of the enzyme that it encodes, PRPP
amidotransferase. We have previously demonstrated that
Table 1 Excreted nucleoside concentrations of the strains used in this work
Strain Genotype Parental strain Inosine (mg/L) Guanosine (mg/L)
A4 Wild type - 11.1 ± 2.4 75.3 ± 4.2
A5 Wild type - 6.3 ± 2.3 53.3 ± 5.1
A6 Wild type - 6.0 ± 4.2 64.1 ± 8.2
A7 Wild type - 11.4 ± 1.3 33.4 ± 2.7
A8 Wild type - 5.4 ± 1.0 15.3 ± 4.2
A9 Wild type - 2.8 ± 1.1 81.7 ± 7.1
A10 Wild type - 6.6 ± 2.3 77.8 ± 4.1
I0 *GPD:ADE4des A4 12.5 ± 2.0 77.2 ± 6.1
I1 GPD:ADE4des, ΔADE12 I0 144.1 ± 7.3 92.8 ± 8.5
I2 GPD:ADE4des, ΔADE12, ΔIMD3 I1 227.9 ± 9.1 70.9 ± 6.2
I3 GPD:ADE4des, ΔADE12, ΔIMD3, GPD:IMD3 I2 44.51 ± 6.3 137.1 ± 3.4
I4 GPD:ADE4des, ΔADE12, ΔPNP1 I1 268.8 ± 8.1 138.0 ± 6.9
I5 GPD:ADE4des, ΔADE12, GPD:ISN1 I1 145.2 ± 5.1 92.2 ± 7.1
I6 GPD:ADE4des, ΔADE12, ΔIMD3, ΔPNP I4 76.3 ± 4.8 27.1 ± 4.3
I7 GPD:ADE4des, ΔADE12, GPD:GUA1 I1 143.7 ± 6.2 91.3 ± 4.5
I8 GPD:ADE4des, ΔADE12, RIB7p:RIB1 I1 136.4 ± 8.2 100.0 ± 4.1
*This strain has been described previously in [17].
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this mutant raises riboflavin production significantly
[17]. In fact, increased nucleoside production levels
brought about by the deregulation of this enzyme in E.
coli, C. glutamicum and B. subtilis have also been re-
ported [6,7,12]. We therefore used this strain (I0) as the
starting point for further genetic modifications. As
shown in Figure 3 and Table 1, I0 excreted inosine and
guanosine at similar levels to A4, indicating that most of
the excess metabolic flux through the purine pathway is
directed to riboflavin [17].
With the purine pathway enhanced in the I0 strain, we
next attempted to further raise the flux through the
guanine pathway to the detriment of the adenineFigure 3 Extracellular concentrations of inosine and guanosine.
Cultures of A. gossypii were grown for five days in flasks containing
MA2. Error bars represent the standard deviations of three
independent experiments.pathway. To accomplish this, we depleted the ADE12
gene that codes for adenylosuccinate synthase, the first
enzyme in the adenine nucleotide pathway after the
branch point between the GMP and AMP pathways
(Figure 1). The resulting strain (I1) was auxotrophic for
adenine but was able to grow at normal rates in rich
medium and excreted about 13 times more inosine and
1.2 times more guanosine than A4 (Figure 3 and Table 1).
These data suggest that the excess of IMP is, to a greater
extent, converted to inosine, which is subsequently ex-
creted to the medium and, to a lesser extent, directed to
the guanine pathway and finally converted to riboflavin.
Accordingly, I1 produces 2.5-fold higher amounts of
riboflavin than A4 (data not shown).
We next disrupted the gene IMD3 in the I1 strain to
generate I2. IMD3 encodes IMP dehydrogenase, the first
enzyme in the guanine pathway after the branch point
between the GMP and AMP pathways. I2 is auxotrophic
for adenine and guanine and its growth rate is reduced
even in rich medium. By blocking both the adenine
(ΔADE12) and the guanine (ΔIMD3) pathways, excess
IMP is converted into inosine, as demonstrated by an al-
most 20-fold increase in the levels of excreted inosine of
I2 with respect to A4 (Figure 3 and Table 1), even
though the dry weight of I2 was lower than that of A4,
due to its reduced growth rate. As expected, the ex-
creted guanosine levels were lower in I2 than in A4
(Table 1).
We next attempted to direct the excess IMP into the
guanine nucleotide pathway by overexpressing the IMD3
gene (encoding IMP dehydrogenase), aiming to increase
Figure 4 Extracellular and intracellular purines in A. gossypii
engineered strains. Intracellular concentration of nucleotides (IMP,
XMP, GMP and AMP), and extracellular concentration of nucleosides
(inosine, xanthosine and guanosine) and nucleobases (hypoxanthine,
xanthine, guanine and adenine) in A. gossypii engineered strains.
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duced the IMD3 gene into I1, under the control of the
strong constitutive glyceraldehyde 3-phosphate dehydro-
genase (GPD) promoter, generating strain I3. As ex-
pected, I3 recovered prototroph for guanine and the
excreted guanosine levels increased by about 2-fold, as
compared to A4, to the detriment of inosine (Figure 3
and Table 1).
We also constructed a different strain, I4, in which
the gene PNP1 -which encodes the enzyme purine-
nucleoside phophorylase- was disrupted to prevent the
transformation of nucleosides into their respective nucleo-
bases. I4 respectively excreted approximately 24- and
2-fold more inosine and guanosine than A4 (Figure 3
and Table 1).
Finally, we generated a strain, I5, in which the ISN1
gene -encoding the enzyme IMP-specific 5′-nucleotid-
ase- was overexpressed in order to enhance nucleoside
production from the respective nucleotide. However, I5
did not show any significant increase in nucleoside ex-
cretion, indicating that the ISN1 gene does not limit nu-
cleoside production in A. gossypii.
We next introduced the three modifications that most
increased nucleoside levels in the culture medium into
I0, i.e. ΔADE12, ΔIMD3 and ΔPNP1, to generate strain
I6. This strain exhibited a rather limited growth pattern
even in rich medium (data not shown). Nonetheless,
even though the total levels of excreted nucleosides per
liter of culture were lower than for the other strains
(Figure 3 and Table 1), I6 showed the best production ti-
ters per cell dry weight (85- and 3-fold more inosine and
guanosine than A4 respectively). In fact, when hypoxan-
thine, guanine and adenine were added to the culture
medium, I6 almost recovered wild-type growth rates and
excreted high amounts of nucleosides; despite this, these
amounts were still below those ones observed for I4
(Additional file 2: Figure S1). Accordingly, we did not
further consider this strain as a potential biotechno-
logical tool.
In sum, by using a classical metabolic engineering ap-
proach that targeted purine nucleotide biosynthesis we
obtained A. gossypii strains in which inosine excretion to
the culture medium was significantly improved, and
increased 25-fold with respect to the wild-type strain
A4. The most favourable modifications included the
overexpression of a deregulated ADE4 mutant gene and
the deletion of ADE12 plus either IMD3 (I2) or PNP1
(I4). The combinations of all four mutations simultan-
eously afforded strains with compromised cell viability,
and hence were not useful for industrial use.
The increased metabolic flux through the de novo pur-
ine nucleotide pathway is mostly directed to inosine ex-
cretion in the mutant strains. We further determined the
intracellular levels of the nucleotides, nucleosides andnucleobases that participate in the purine biosynthetic
pathway, as shown in Figure 1 of A4, I1, I2 and I4, since
these are the wild-type and the strains with the highest
biotechnological potential. This would not only allow us
to further explore the effects of the mutations on the
purine pathway but also to identify potential bottlenecks
susceptible to manipulation in order to increase nucleo-
side production.
Intriguingly, the total nucleoside (guanosine, xantho-
sine, inosine and adenosine) intracellular levels, in the
nmol/g range, were about three orders of magnitude
lower than the extracellular ones (Figure 4). Moreover,
the variations in extracellular nucleoside levels between
the wild-type and engineered strains (Figure 3) were sig-
nificantly more marked than the corresponding varia-
tions in the intracellular metabolites (Figure 5).
In the wild-type strain, A4, guanosine levels were
higher than those of inosine, in accordance with the ex-
creted nucleosides in A4 (Figure 2A). As expected,
ade12 depletion (strains I1, I2 and I4) redirected the
purine metabolic flux towards inosine/GMP at the ex-
pense of AMP production, as reflected in a marked de-
crease in AMP and adenosine intracellular levels in
these strains (Figure 5). Remarkably, the excess IMP
generated in these strains was preferentially directed to
inosine and hypoxanthine rather than to GMP/guano-
sine production (Figure 5). This was subsequently
reflected in the respective nucleoside extracellular levels:
while a marked increase in excreted inosine was ob-
served in the mutant strains studied, only subtle changes
in excreted guanosine were observed (Figure 3 and
Table 1).
Thus, the concentration of inosine in the culture medium
of A. gossypii flask fermentations is proportional to the
metabolic flux through the purine pathway, representing a
AB
C
Figure 5 Intracellular metabolites of the purine pathway in strains
A4, I1, I2 and I4. A. GMP, XMP, AMP and IMP nucleotide concentrations.
B. Guanosine, xanthosine, adenosine and inosine nucleoside
concentrations. C. Guanine, xanthine, adenine and hypoxanthine
nucleobase concentrations.
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relative differences in metabolic engineering approaches.
Interestingly, all strains, except I2 (where IMD3 was dis-
rupted), accumulated intracellular XMP, suggesting eithera tight regulation at this level or a low efficiency of the
enzyme GMP synthase. To overcome this, we used I1 as
the parental strain to construct I7, in which the GUA1
gene -encoding the enzyme GMP synthase- was overex-
pressed by placing it under the control of the strong con-
stitutive promoter of GPD. However, I7 did not show
higher levels of excreted guanosine (Table 1) but instead
increased the production of riboflavin (data not shown),
indicating that most of the excess metabolic flux through
the guanine nucleotide pathway was directed beyond
GMP/GTP to riboflavin synthesis, as has been previ-
ously reported by our lab [17,18]. We thus decided to
down-regulate riboflavin synthesis by placing the RIB1
gene (which catalyzes the first and one of the limiting
steps of riboflavin biosynthesis) under the control of
the RIB7 promoter, generating strain I8. The RIB7 pro-
moter has been shown to produce low transcription
levels and can therefore be used to down-regulate gene
expression in A. gossypii (Ledesma-Amaro et al., submitted
manuscript). Indeed, this strain showed decreased ribofla-
vin production (not shown), as expected, but guanosine
excretion did not increase significantly (Table 1).
Taken together, our data show that the excess meta-
bolic flux through the purine pathway in A. gossypii is
mostly derived to produce either riboflavin (in the late
growth phase) or inosine (in the mid-early growth
phase), which are subsequently excreted to the culture
medium. Accordingly, inosine excretion might act as a
mechanism to prevent an overflow through the guanine
nucleotide pathway that would alter the guanine nucleo-
tide pool and compromise cell viability.
To conclude, we have constructed A. gossypii strains
with improved inosine excretion levels up to 0.27 g/L in
culture media containing 20 g/L of glucose. Moreover,
as an initial approach we have only focused on the sys-
tematic manipulation of the de novo purine biosynthetic
pathway, but it is envisaged that additional manipula-
tions of the central metabolism, global metabolic regula-
tors, the salvage pathway, as well as transporters, will
improve nucleoside excretion, as described for other or-
ganisms [10]. In any case, although further strain ma-
nipulation and optimization of the culture medium
composition and fermentation conditions are required,
our results demonstrate that A. gossypii is a promising
candidate for use in the production of nucleosides at in-
dustrial scale. In fact, the nucleoside production titers
described in this work are comparable to those of ribo-
flavin (10–100 mg/L) when grown in flasks containing
MA2 rich medium but A. gossypii wild-type strains are
able of produce up to 5.5 g/L of riboflavin after partial
optimization of the medium composition [24]. Likewise,
higher nucleoside production titers are envisaged after
systematic optimization of large-scale fermentation con-
ditions in A. gossypii.
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first description of an eukaryotic organism for potential
use in industrial nucleoside production. It should be
remarked here that A. gossypii presents several advan-
tages with respect to the bacterial systems currently used
in industry: i) the convenience of the filtration/centrifu-
gation processes to separate the biomass from the
culture medium owing to the much larger size of the
mycelia with respect to bacterial cells, ii) A. gossypii
barely excretes any extracellular fermentative by-products;
accordingly, nucleoside-enriched medium could be readily
separated from the mycelium by simple and non-expensive
filtration and/or centrifugation procedures, facilitating
downstream processing to a considerable extent and iii)
the availability of protocols for large-scale fermentation
already implemented for riboflavin production.
Conclusions
Using a rational metabolic engineering approach, aided by
computational predictions, we have obtained Ashbya gossy-
pii strains with improved nucleoside production titers that
are very promising candidates for further optimization and
use in nucleoside production at industrial level.
Methods
A. gossypii strains, media, and growth conditions
All the A. gossypii strains described in this manuscript
are listed in Table 1. They were cultured at 28°C using
MA2 rich medium [25]. Transformation, sporulation
conditions and spore isolation were as described in de-
tail elsewhere [26]. Gene disruption and overexpression
were performed as previously published [17,20,27]. Gene
down-regulation was achieved by placing the desired
gene under the control of the RIB7 promoter, which ensures
low transcription levels (Ledesma-Amaro et al., submitted
manuscript). Correct DNA integration was corroborated
by sequencing for all the strains used in this study.
Metabolite determination
Mycelia from 5 mL culture broth were harvested by
filtration on filter paper, dried overnight at 100°C and
weighed. Filtered medium was passed through a 0.2 μm
PVDF membrane (Acrodisc® LC; Pall, Life Sciences) and
injected into an AQUASIL C18 140×4.6 mm column
(Thermo Scientific) connected to an HPLC device (Agilent
1120 Compact LC) to determine extracellular nucleoside
concentrations by monitoring absorbance at 260 nm.
The separation of nucleosides was achieved by using an
isocratic flow of phosphate buffer, pH 5.5, plus 0.5% of
acetonitrile. Quantification was carried out using a cali-
bration curve prepared with pure standards of inosine and
guanosine (Sigma-Aldrich). All analyses were performed
using three biological replicates.Metabolism quenching and metabolite extraction were
carried out as described [28,29], using the mycelia ob-
tained from 7 mL of culture broth. Briefly, samples were
quenched by the addition of methanol at −40°C, followed
by boiling ethanol, and extracted upon the addition of
acetonitrile by mechanical homogenization and subse-
quent chloroform/chloromethane organic extraction steps.
The intracellular concentrations of the metabolites in the
purine pathway were determined following previously
published methodologies [30].
Additional files
Additional file 1: Table S1. Reaction carrying flux according to the
genome scale metabolic model iRL766. Column A represents the
reaction carrying flux when the production of biomass is maximized.
Column E and I represents the reaction carrying flux when the
production of inosine and guanosine are respectively maximized.
Additional file 2: Figure S1. Extracellular nucleosides in the strain
I6. A. Extracellular concentrations of inosine and guanosine in mg per
liter of culture. B. Extracellular concentrations in mg of inosine and
guanosine per gram of CDW. Cultures were grown for five days in flasks
containing MA2. Where indicated, hypoxanthine, guanine and adenine
nucleobases at a final concentration of 150 μM were added to the
media. Error bars represent the standard deviations of three independent
experiments.
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